Figure 1.

Effects of 26 weeks of treatment with liraglutide or placebo on the expression of inflammatory genes in isolated peripheral blood mononuclear cells in patients with T2D. Gene expression of selected inflammatory genes at baseline and end-of treatment measured by quantitative real-time polymerase chain reaction. Levels are for the individual participants in the liraglutide (n = 31) and the placebo (n = 23) treated group. Ct cycle threshold. ∆Ct = Ct (gene of interest) – Ct (ACTB), a decrease in ∆Ct values can be interpreted as an upregulation of the gene. P values from paired t-test. EOT end-of-treatment.